Matching articles for "Oxycontin"
Issue 1665 · December 12, 2022
Opioids for Pain

A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):193-200
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Issue 1665 · December 12, 2022
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

View the Comparison Table: Some Oral/Transdermal Opioid Analgesics

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e199-202
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Issue 1544 · April 9, 2018
Opioids for Pain

Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations…

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):57-64
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Issue 1544 · April 9, 2018
Comparison Table: Some Oral/Topical Opioid Analgesics (online only)

View the Comparison Table: Some Oral/Topical Opioid Analgesics

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):e64-7
View the Comparison Table: Some Oral/Topical Opioid Analgesics
Issue 1522 · June 5, 2017
Abuse-Deterrent Opioids

Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article on this subject,…

Med Lett Drugs Ther. 2017 Jun 5; 59(1522):95-6
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article on this subject, several new abuse-deterrent opioid formulations have been approved by the FDA, including an oxycodone tablet formulation ( Roxybond – Inspirion) that is the first immediate-release opioid product FDA-approved to include claims of abuse deterrence in its labeling. No opioid formulation prevents consumption of a large number of intact dosage units, the most common method of abuse. Abuse-deterrent formulations have one or more properties that make their intentional nontherapeutic use more difficult, less attractive, or less rewarding.
Issue 1519 · April 24, 2017
Arymo ER - A New Abuse-Deterrent Morphine Formulation

The FDA has approved Arymo ER (Egalet), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain severe enough to require daily, around-the-clock, long-term opioid…

Med Lett Drugs Ther. 2017 Apr 24; 59(1519):68-9
The FDA has approved Arymo ER (Egalet), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Arymo ER can only be marketed to deter abuse by injection because another single-entity, extended-release morphine product, MorphaBond , which has not been marketed to date, has marketing exclusivity for deterrence of abuse by the intranasal route through October 2018.
Issue 1497 · June 20, 2016
A New Abuse-Deterrent Opioid - Xtampza ER

The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid…

Med Lett Drugs Ther. 2016 Jun 20; 58(1497):77-8
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Issue 1476 · August 31, 2015
Abuse-Deterrent Opioid Formulations

Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Three available opioid formulations,…

Med Lett Drugs Ther. 2015 Aug 31; 57(1476):119-21
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Three available opioid formulations, OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER (Purdue), now include claims of abuse deterrence in their package inserts.
Issue 1468 · May 11, 2015
Extended-Release Hydrocodone (Hysingla ER) for Pain

The FDA has approved a second extended-release (ER) formulation of the oral opioid agonist hydrocodone ( Hysingla ER – Purdue) for management of pain severe enough to require continuous long-term therapy and…

Med Lett Drugs Ther. 2015 May 11; 57(1468):71-2
The FDA has approved a second extended-release (ER) formulation of the oral opioid agonist hydrocodone ( Hysingla ER – Purdue) for management of pain severe enough to require continuous long-term therapy and for which alternative treatment options are inadequate. Hysingla ER tablets have abuse-deterrent properties to discourage their misuse.
Issue 1447 · July 21, 2014
Extended-Release Oxycodone and Acetaminophen (Xartemis XR)

The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen ( Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is…

Med Lett Drugs Ther. 2014 Jul 21; 56(1447):59-61
The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen ( Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is available in the US as a single entity in oral immediate-release ( Oxecta , and others) and extendedrelease (OxyContin) formulations. Immediate-release oxycodone is also available in combination with aspirin ( Percodan , and others), acetaminophen ( Percocet , and others), or ibuprofen (see Table 1).
Issue 1444 · June 9, 2014
Extended-Release Hydrocodone (Zohydro ER) for Pain

The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone ( Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which…

Med Lett Drugs Ther. 2014 Jun 9; 56(1444):45
The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone ( Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which alternative treatment options are inadequate. Zohydro ER is the first single-ingredient hydrocodone product to be marketed in the US. Hydrocodone has been available for years in combination with acetaminophen ( Vicodin , and others) or ibuprofen ( Vicoprofen , and others).
Issue 128 · April 1, 2013
Drugs for Pain

Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less…

Treat Guidel Med Lett. 2013 Apr; 11(128):31-42
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 92 · April 1, 2010
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is…

Treat Guidel Med Lett. 2010 Apr; 8(92):25-34
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1318 · August 10, 2009
Tapentadol (Nucynta) - A New Analgesic

The FDA has approved tapentadol hydrochloride (Nucynta - Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients ≥18 years old. It has been classified as a Schedule II…

Med Lett Drugs Ther. 2009 Aug 10; 51(1318):61-2
The FDA has approved tapentadol hydrochloride (Nucynta - Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients ≥18 years old. It has been classified as a Schedule II controlled substance
Issue 56 · April 1, 2007
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants…

Treat Guidel Med Lett. 2007 Apr; 5(56):23-32
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants and anticonvulsants have been used to treat neuropathic pain. Combining two different types of analgesics may nprovide an additive analgesic effect without increasing adverse effects.
Issue 1251 · January 1, 2007
Oral Oxymorphone (Opana)

Oxymorphone hydrochloride, a semi-synthetic opioid agonist, has been available for many years in the US as Numorphan (Endo) for parenteral use and as a rectal suppository. Now it has been approved by the FDA…

Med Lett Drugs Ther. 2007 Jan 1; 49(1251):3-4
Oxymorphone hydrochloride, a semi-synthetic opioid agonist, has been available for many years in the US as Numorphan (Endo) for parenteral use and as a rectal suppository. Now it has been approved by the FDA for oral administration as an immediate-release (IR) tablet (Opana) for treatment of moderate to severe acute pain, and as an extended-release tablet (Opana ER) for treatment of moderate to severe pain in patients requiring continuous opioid treatment for an extended period of time.
Issue 1225 · January 2, 2006
A Combination of Oxycodone and Ibuprofen (Combunox) for Pain

A fixed-dose combination of oxycodone 5 mg and ibuprofen 400 mg ( Combunox - Forest Laboratories) is now available and is being heavily advertised for short-term treatment of moderate to severe acute pain.

Med Lett Drugs Ther. 2006 Jan 2; 48(1225):3-4
A fixed-dose combination of oxycodone 5 mg and ibuprofen 400 mg ( Combunox - Forest Laboratories) is now available and is being heavily advertised for short-term treatment of moderate to severe acute pain.
Issue 1214 · August 1, 2005 Free
In Brief: Palladone Withdrawn

The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that…

Med Lett Drugs Ther. 2005 Aug 1; 47(1214):61
The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that risk, the FDA asked the manufacturer (Purdue) to withdraw the drug from the market (FDA News. July 13, 2005; FDC Reports – “The Pink Sheet” July 18, 2005; 67:3) .
Issue 1204 · March 14, 2005
Palladone for Chronic Pain

A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride ( Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with…

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):21-3
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride ( Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms ( Dilaudid , and others).
Issue 23 · July 1, 2004
Drugs for Pain

Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of…

Treat Guidel Med Lett. 2004 Jul; 2(23):47-54
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of as analgesics, such as antidepressants, which can act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Combining two different types of analgesics may provide an additive analgesic effect without necessarily increasing adverse effects.
Issue 1137 · August 19, 2002
Tests for Drugs of Abuse

Testing for drug use has become increasingly common, not only in health care, but also in drug rehabilitation, in the military, at the workplace, after accidents and in the criminal justice system.…

Med Lett Drugs Ther. 2002 Aug 19; 44(1137):71-3
Testing for drug use has become increasingly common, not only in health care, but also in drug rehabilitation, in the military, at the workplace, after accidents and in the criminal justice system. Performance-enhancing drugs such as anabolic steroids, growth hormone ( Genotropin , and others) and erythropoietin ( Procrit, Epogen ) are not discussed here.
Issue 1125 · March 4, 2002
Acute Reactions to Drugs of Abuse

Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.

Med Lett Drugs Ther. 2002 Mar 4; 44(1125):21-4
Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.
Issue 1113 · September 17, 2001
Oxycodone OxyContin

Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to…

Med Lett Drugs Ther. 2001 Sep 17; 43(1113):80-1
Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to reinforce the FDA-approved indication "...for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time..."
Issue 1085 · August 21, 2000
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought…

Med Lett Drugs Ther. 2000 Aug 21; 42(1085):73-8
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Non-opioids can be given concurrently with opioids for an additive analgesic effect.